MedTrace Logo

Study to Evaluate the Efficacy and Safety of P-3073 Nail Solution in the Treatment of Mild to Moderate Psoriatic Fingernail/s

NCT03079973 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2018-01-10

No results posted yet for this study

Summary

The objective of this phase III study is to evaluate the efficacy, systemic safety and local tolerability of P-3073 (calcipotriene 0.005%) nail solution in patients with mild to moderate psoriatic fingernail/s.

Conditions

  • Nail Psoriasis

Interventions

DRUG

P-3073 (calcipotriene 0.005%)

Topical solution P-3073 (calcipotriene 0.005%) once daily for 24 weeks.

DRUG

Vehicle of P-3073

Once daily for 24 weeks.

Sponsors & Collaborators

  • Almirall, S.A.

    collaborator INDUSTRY

  • Polichem S.A.

    lead INDUSTRY

Principal Investigators

  • Maurizio Caserini, MD · Polichem SA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-15
Primary Completion
2018-07-31
Completion
2018-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03079973 on ClinicalTrials.gov